JSPR

Jasper Therapeutics, Inc. (JSPR) - 10-K Summary

Business Context and Reporting Period

Company: Jasper Therapeutics, Inc.
Filing Type: Annual Report on Form 10-K
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Jasper is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell-driven diseases, specifically Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU), and asthma. The company's lead product candidate is briquilimab, a monoclonal antibody that blocks the SCF/KIT pathway to deplete mast cells. In July 2025, the company discontinued its stem cell transplant programs (including SCID) to focus exclusively on mast cell indications.

Key Financial Metrics (Year Ended Dec 31, 2025)

Note: The company has no revenue and is not profitable. Margins and debt ratios are not applicable as there is no revenue and no outstanding debt.

Material Changes vs. Prior Period

• Net Loss Increase: Net loss increased by $4.5 million (6%) year-over-year, driven by higher R&D program costs and restructuring charges.
• Restructuring and Impairment: In July 2025, the company implemented a corporate reorganization reducing its workforce by approximately 50% (22 employees), incurring $2.3 million in restructuring costs. In December 2025, the company ceased vivarium operations, recognizing a $1.1 million impairment loss on fixed assets and right-of-use assets.
• Capital Raise: In September 2025, the company completed an underwritten public offering raising net proceeds of $27.5 million. Additionally, $6.5 million was raised via an At-The-Market (ATM) offering during the year.
• Warrant Liability: A non-cash gain of $8.5 million was recorded due to a decrease in the fair value of warrant liabilities issued in the September 2025 offering.
• Program Discontinuation: The SCID and other stem cell transplant programs were discontinued in July 2025 to extend cash runway.

Guidance, Outlook, and Risks

Going Concern: Management has concluded that substantial doubt exists about the company's ability to continue as a going concern for at least one year from the filing date. Current cash of $28.7 million is insufficient to fund operations for the next 12 months without additional financing.

Clinical Outlook:

• CSU (BEACON Study): Positive preliminary data reported. An investigation into anomalous efficacy results in two cohorts concluded the issue was patient selection criteria, not product quality. New data from re-enrolled patients showed deep clinical responses.
• CIndU (SPOTLIGHT Study): Positive data reported with high rates of clinical and complete response.
• Asthma (ETESIAN Study): Enrollment was halted in July 2025 due to the investigation of the drug lot used in the CSU study. Future development depends on capital availability and competitive landscape.

Key Risks:

• Liquidity: Immediate need for additional capital to fund operations and clinical trials.
• Regulatory: No products approved; success depends on future clinical trial results and FDA/EMA approval.
• Legal: Subject to a shareholder class action lawsuit (filed Sept 2025) alleging misstatements regarding clinical studies, and related derivative suits.
• Manufacturing: Reliance on a single manufacturer (Lonza) for clinical supply.

Investor Verification Checklist

• Cash Runway: Verify the timeline for the next capital raise given the $28.7 million cash balance and $77M annual burn rate.
• Legal Proceedings: Monitor the status of the Grant v. Jasper Therapeutics class action and derivative suits filed in late 2025.
• Clinical Data Integrity: Review the final data from the re-enrolled BEACON study cohorts to confirm the resolution of the patient selection issue.
• Warrant Liability: Assess the impact of the $16.2 million warrant liability on future equity dilution and balance sheet volatility.
• Management Transition: Note the departure of CEO Ron Martell in January 2026 and the appointment of Jeet Mahal as the new CEO.